<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94156">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989455</url>
  </required_header>
  <id_info>
    <org_study_id>LA42-0113</org_study_id>
    <nct_id>NCT01989455</nct_id>
  </id_info>
  <brief_title>A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers</brief_title>
  <official_title>A Single Center, Phase I, Double-blind, Placebo-controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Deferiprone Administered by Intravenous Infusion to Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ApoPharma</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, randomized, double-blind, placebo-controlled, adaptive sequential
      ascending-dose study for the evaluation of the safety, tolerability, and pharmacokinetics of
      single doses of deferiprone administered by intravenous infusion to healthy males and
      females. A bioavailability comparison will be included.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: the time to reach maximum observed plasma concentration (Tmax) will be evaluated following intravenous administration of deferiprone or placebo.</measure>
    <time_frame>Pre-infusion and 0.17, 0.33, 0.5, 0.75 (collected during the intravenous infusion) and 1 (immediately after the end of intravenous infusion), 1.33, 1.67, 2, 2.5, 3,4,6,9,12 and 14 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The pharmacokinetic parameter, Tmax, will be assessed over a 14 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: the maximum observed plasma concentration (Cmax) will be evaluated following a single intravenous administration of deferiprone or placebo.</measure>
    <time_frame>Pre-infusion  and 0.17, 0.33, 0.5, 0.75 (collected during the intravenous infusion) and 1 (immediately after the end of intravenous infusion), 1.33, 1.67, 2, 2.5, 3,4,6,9,12 and 14 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The pharmacokinetic parameter, Cmax, will be assessed over a 14 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: area under the serum concentration time curve (AUC) will be evaluated following a single intravenous administration of deferiprone or placebo.</measure>
    <time_frame>Pre-infusion and 0.17, 0.33, 0.5, 0.75 (collected during the intravenous infusion) and 1 (immediately after the end of intravenous infusion), 1.33, 1.67, 2, 2.5, 3,4,6,9,12 and 14 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The pharmacokinetic parameter, AUC, will be assessed over a 14 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: the terminal elimination half-life (T1/2el) will be evaluated following a single intravenous administration of deferiprone or placebo.</measure>
    <time_frame>Pre-infusion and 0.17, 0.33, 0.5, 0.75 (collected during the intravenous infusion) and 1 (immediately after the end of intravenous infusion), 1.33, 1.67, 2, 2.5, 3,4,6,9,12 and 14 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The pharmacokinetic parameter, T1/2el will be assessed over a 14 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single ascending doses of deferiprone when administered by intravenous infusion in healthy volunteers.</measure>
    <time_frame>Pre-dose, 0.5-24 hours post-dose and 5 days after dosing.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability will be evaluated through the assessment of adverse events (AEs), physical examination, vital signs, ECG, patient monitoring and laboratory tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: area under the serum concentration time curve (AUC) will be evaluated following a single intravenous or oral administration of deferiprone.</measure>
    <time_frame>Pre-dose to 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The pharmacokinetic parameter, AUC, will be assessed over a 24 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.The comparison between the oral and intravenous doses of deferiprone and deferiprone 3-O-glucuronide will be assessed to obtain an absolute bioavailability.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 500mg deferiprone or placebo administered via intravenous infusion.
First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.
Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.
Randomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.
Subjects enrolled to cohort 2 will receive an oral dose of deferiprone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.
Randomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.
First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.
Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <description>Deferiprone for infusion, 10mg/mL for intravenous infusion.
Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Ferriprox</other_name>
    <other_name>DFP</other_name>
    <other_name>L1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: normal saline solution.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Saline solution.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Healthy adult males or females, at least 18 years old but not older than 50 years.

          2. Body weight at least 60kg.

          3. Body Mass Index (BMI) ≥ 18.50 and ≤ 30.00 kg/m2

          4. Medically healthy with clinically insignificant screening results (e.g., laboratory
             profiles, medical history, ECG, vital signs, physical examination.

          5. Non or ex-smoker (someone who has completely stopped smoking 6 months before study
             start)

          6. For females, negative result on a serum pregnancy test.

        Main Exclusion Criteria:

          1. Absolute neutrophil count (ANC) &lt;1.5x10^9/L.

          2. History or presence of hypersensitivity to deferiprone or any related products.

          3. History or presence of gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs.

          4. Presence of significant cardiovascular, pulmonary, hematologic, neurologic,
             psychiatric, endocrine, immunologic or dermatologic disease.

          5. Any history of tuberculosis (TB) or prophylaxis for TB.

          6. Suicidal tendency, history of seizures, head trauma with coma or
             craniotomy/trepanation, state of confusion or relevant psychiatric disease.

          7. Inadequate venous access in either arm.

          8. Presence of out-of-range cardiac interval or clinically significant ECG abnormalities
             (PR &lt;110 msec or &gt; 220 msec, QRS &lt;60 msec or &gt;119 msec, QTcB &gt; 450 msec for males and
             &gt;460 msec for females).

          9. Use of acetaminophen, acetylsalicylic acid (ASA), or non-steroidal anti-inflammatory
             drugs (NSAIDs) in the previous 7 days before study start.

         10. Use of any enzyme-modifying drugs, including strong inhibitors of P450 (CYP) enzymes
             such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole,
             ketoconazole, diltiazem, and HIV antivirals OR strong inducers of CYP enzymes such
             as: barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin, and St. John's
             wart within 28 days prior to study start.

         11. Maintenance therapy with any drug, or significant history of drug dependency or
             alcohol abuse.

         12. Had a clinically significant illness during the 28 days prior to study start.

         13. Receipt of an investigational product in another clinical trial within 28 days prior
             prior to study start.

         14. Enrolment in a previous cohort of this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Tricta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ApoPharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma Inc.</name>
      <address>
        <city>Mont-Royal</city>
        <state>Quebec</state>
        <zip>H3P3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>November 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Deferiprone</keyword>
  <keyword>DFP</keyword>
  <keyword>L1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
